vs
Side-by-side financial comparison of Acadian Asset Management Inc. (AAMI) and ANI PHARMACEUTICALS INC (ANIP). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $172.2M, roughly 1.4× Acadian Asset Management Inc.). Acadian Asset Management Inc. runs the higher net margin — 20.2% vs 11.1%, a 9.0% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 2.6%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 27.6%).
United Asset Management was an American holding company headquartered in Boston, Massachusetts.
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
AAMI vs ANIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $172.2M | $247.1M |
| Net Profit | $34.7M | $27.5M |
| Gross Margin | — | — |
| Operating Margin | 33.3% | 14.1% |
| Net Margin | 20.2% | 11.1% |
| Revenue YoY | 2.6% | 29.6% |
| Net Profit YoY | -18.4% | 367.5% |
| EPS (diluted) | $0.97 | $1.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $172.2M | $247.1M | ||
| Q3 25 | $144.2M | $227.8M | ||
| Q2 25 | $127.4M | $211.4M | ||
| Q1 25 | $119.9M | $197.1M | ||
| Q4 24 | $167.8M | $190.6M | ||
| Q3 24 | $123.1M | $148.3M | ||
| Q2 24 | $109.0M | $138.0M | ||
| Q1 24 | $105.7M | $137.4M |
| Q4 25 | $34.7M | $27.5M | ||
| Q3 25 | $15.1M | $26.6M | ||
| Q2 25 | $10.1M | $8.5M | ||
| Q1 25 | $20.1M | $15.7M | ||
| Q4 24 | $42.5M | $-10.3M | ||
| Q3 24 | $16.9M | $-24.2M | ||
| Q2 24 | $11.0M | $-2.3M | ||
| Q1 24 | $14.6M | $18.2M |
| Q4 25 | 33.3% | 14.1% | ||
| Q3 25 | 18.4% | 15.9% | ||
| Q2 25 | 12.7% | 6.6% | ||
| Q1 25 | 26.6% | 13.3% | ||
| Q4 24 | 38.7% | -2.3% | ||
| Q3 24 | 21.9% | -13.8% | ||
| Q2 24 | 18.9% | 3.7% | ||
| Q1 24 | 21.7% | 14.8% |
| Q4 25 | 20.2% | 11.1% | ||
| Q3 25 | 10.5% | 11.7% | ||
| Q2 25 | 7.9% | 4.0% | ||
| Q1 25 | 16.8% | 8.0% | ||
| Q4 24 | 25.3% | -5.4% | ||
| Q3 24 | 13.7% | -16.3% | ||
| Q2 24 | 10.1% | -1.7% | ||
| Q1 24 | 13.8% | 13.2% |
| Q4 25 | $0.97 | $1.14 | ||
| Q3 25 | $0.42 | $1.13 | ||
| Q2 25 | $0.28 | $0.36 | ||
| Q1 25 | $0.54 | $0.69 | ||
| Q4 24 | $1.11 | $-0.45 | ||
| Q3 24 | $0.45 | $-1.27 | ||
| Q2 24 | $0.29 | $-0.14 | ||
| Q1 24 | $0.37 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $285.6M |
| Total DebtLower is stronger | $200.0M | — |
| Stockholders' EquityBook value | — | $540.7M |
| Total Assets | $677.0M | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $285.6M | ||
| Q3 25 | — | $262.6M | ||
| Q2 25 | — | $217.8M | ||
| Q1 25 | — | $149.8M | ||
| Q4 24 | — | $144.9M | ||
| Q3 24 | — | $145.0M | ||
| Q2 24 | — | $240.1M | ||
| Q1 24 | — | $228.6M |
| Q4 25 | $200.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $275.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $540.7M | ||
| Q3 25 | — | $505.8M | ||
| Q2 25 | — | $436.8M | ||
| Q1 25 | — | $418.6M | ||
| Q4 24 | — | $403.7M | ||
| Q3 24 | — | $405.9M | ||
| Q2 24 | — | $455.8M | ||
| Q1 24 | — | $452.0M |
| Q4 25 | $677.0M | $1.4B | ||
| Q3 25 | $751.4M | $1.4B | ||
| Q2 25 | $672.3M | $1.3B | ||
| Q1 25 | $677.3M | $1.3B | ||
| Q4 24 | $703.2M | $1.3B | ||
| Q3 24 | $555.2M | $1.3B | ||
| Q2 24 | $533.1M | $920.8M | ||
| Q1 24 | $544.9M | $914.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.4M | $30.4M |
| Free Cash FlowOCF − Capex | — | $29.1M |
| FCF MarginFCF / Revenue | — | 11.8% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | -0.07× | 1.10× |
| TTM Free Cash FlowTrailing 4 quarters | — | $171.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.4M | $30.4M | ||
| Q3 25 | $-23.9M | $44.1M | ||
| Q2 25 | $61.6M | $75.8M | ||
| Q1 25 | $-48.8M | $35.0M | ||
| Q4 24 | $55.8M | $15.9M | ||
| Q3 24 | $69.6M | $12.5M | ||
| Q2 24 | $45.7M | $17.4M | ||
| Q1 24 | $-40.4M | $18.3M |
| Q4 25 | — | $29.1M | ||
| Q3 25 | — | $38.0M | ||
| Q2 25 | — | $71.8M | ||
| Q1 25 | — | $32.5M | ||
| Q4 24 | — | $13.5M | ||
| Q3 24 | — | $7.7M | ||
| Q2 24 | — | $13.0M | ||
| Q1 24 | — | $13.7M |
| Q4 25 | — | 11.8% | ||
| Q3 25 | — | 16.7% | ||
| Q2 25 | — | 34.0% | ||
| Q1 25 | — | 16.5% | ||
| Q4 24 | — | 7.1% | ||
| Q3 24 | — | 5.2% | ||
| Q2 24 | — | 9.4% | ||
| Q1 24 | — | 10.0% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.7% | ||
| Q2 25 | — | 1.9% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | -0.07× | 1.10× | ||
| Q3 25 | -1.58× | 1.66× | ||
| Q2 25 | 6.10× | 8.87× | ||
| Q1 25 | -2.43× | 2.23× | ||
| Q4 24 | 1.31× | — | ||
| Q3 24 | 4.12× | — | ||
| Q2 24 | 4.15× | — | ||
| Q1 24 | -2.77× | 1.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAMI
Segment breakdown not available.
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
